Merck KGaA, Versant launch Saturnus Bio in USD 50m rare cardiology venture

Saturnus Bio, a precision cardiology company founded by Versant Ventures, has [launched](https://www.businesswire.com/news/home/20260609440189/en/Merck-Collaborates-with-Versant-Ventures-to-Launch-Saturnus-Bio-to-Advance-Treatments-for-Rare-Genetic-Cardiomyopathies) with USD 50 million in upfront funding from Germany's Merck KGaA. The company and financing is part of a research-stage build-to-buy collaboration targeting rare mono-genetic cardiomyopathies, a disease area with no approved therapies addressing the underlying genetic drivers. As per the press release, the deal grants Merck a minority equity stake in Saturnus and exclusive rights to acquire the company for a pre-determined option payment, with additional success-based preclinical milestones also included in the structure. Rick Dewey, MD, an entrepreneur-in-residence at Versant Ventures, serves as CEO of the newly launched company. Saturnus is developing what it describes as first-in-class medicines using targeted gene modulation to address rare single-gene defects that drive cardiomyopathy. The specific gene targets, modality — such as antisense oligonucleotides, siRNA, or base editing — and named drug candidates were not disclosed at launch. The company's pipeline remains at the research and preclinical stage. Rare monogenic cardiomyopathies are caused by inherited mutations in genes involved in cardiac muscle structure and function, including MYBPC3, LMNA, PKP2 and DSP. Collectively, inherited cardiomyopathies affect hundreds of thousands of people worldwide and are associated with heart failure, arrhythmias and sudden cardiac death. Hypertrophic cardiomyopathy has seen two recent approvals, for Bristol Myers Squibb's Camzyos (mavacamten) and Cytokinetics' Myqorzo (aficamten), which improve cardiac function but do not directly address the inherited mutations that drive disease in genetically defined patient populations. Saturnus enters a field where several companies are pursuing genetic medicines for inherited cardiomyopathies. Tenaya Therapeutics is developing gene replacement therapies[ TN-201 ](https://app.allsci.com/news/ASC-NR-0000003533868-1.0-1780484769?query=TN-201)for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-related arrhythmogenic right ventricular cardiomyopathy, while other developers are exploring RNA-based and gene-editing approaches for mutation-driven cardiac diseases. For Merck — which operates in the US and Canada as EMD Serono in healthcare — the collaboration represents an entry into genetically defined cardiovascular disease, an area where the company has had limited previous presence. The Darmstadt, Germany-based company has positioned precision medicine-defined indications as a strategic priority, and the Saturnus partnership reflects an effort to access externally developed platforms in areas where its internal pipeline has limited presence. Versant Ventures has applied a similar build-to-buy model in [prior collaborations](https://app.allsci.com/news/ASC-NR-0000000581354-1.0-1774444664?query=Versant), co-founding companies with established pharmaceutical partners to reduce early-stage capital risk while providing pharma with structured acquisition optionality. *** This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: [https://allsci.com/news/](https://allsci.com/news/) --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/cardiomyopathy-therapies-merck-backs)